Activin signaling through activin receptor type II causes the cachexia- like symptoms in inhibin-deficient mice
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Activins and inhibins, members of the transforming growth factor-beta superfamily, are involved in diverse physiological and developmental processes. We have previously shown that mice deficient in alpha-inhibin develop gonadal sex cord-stromal tumors at an early age. The tumor development is rapidly followed by a wasting syndrome that includes severe weight loss, hepatocellular necrosis around the central vein, and depletion of the parietal cells in the glandular stomach. The liver histology in inhibin-deficient mice is similar to the pathological effects of short-term treatment of rats and mice with recombinant activin A. Consistent with these findings, we have shown that the gonadal tumors in the inhibin-deficient mice secrete high levels of activins. In addition, Northern blot analysis has localized activin receptor type II (ActRII) to the liver. Based on these studies, we postulated that tumor-produced activins act through ActRII to cause the wasting syndrome in inhibin-deficient mice. To test this hypothesis and determine the significance of elevated levels of activin signaling through ActRII in vivo, we generated compound homozygous mutant mice deficient in both alpha-inhibin and ActRII. Despite the continued development of gonadal sex cord-stromal tumors and elevated serum levels of activin A and B, the compound homozygous mutant mice suffered no unusual weight loss, and the stomachs and livers of the majority of the mice were histologically normal. These results demonstrate that increased levels of activin signaling through ActRII in hepatocytes and the glandular stomach causes the hepatocellular necrosis and depletion of parietal cells in the glandular stomach as well as the severe weight loss in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional analysis of activins during mammalian development
Matzuk, M. M., Kumar, T. R., Vassalli, A., Bickenbach, J. R., Roop, D. R., Jaenisch, R., & Bradley, A. (1995) · Nature · doi:10.1038/374354a0 · Cited by 578
Self-citation
Cited by
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940
Induction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907
The Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 820
Genetic Analysis of the Mammalian Transforming Growth Factor-β Superfamily
Chang, H., Brown, C. W., & Matzuk, M. M. (2002) · Endocrine Reviews · doi:10.1210/er.2002-0003 · Cited by 787
The ovary: basic biology and clinical implications
Richards, J. S., & Pangas, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41350 · Cited by 561
Activins and Inhibins: Roles in Development, Physiology, and Disease
Namwanje, M., & Brown, C. W. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021881 · Cited by 294
Origin, differentiation and regulation of fetal and adult Leydig cells
Habert, R., Lejeune, H., & Saez, J. M. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00461-0 · Cited by 294
Jones, K. L., Mansell, A., Patella, S., Scott, B. J., Hedger, M. P., de Kretser, D. M., & Phillips, D. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705971104 · Cited by 280
Inhibins, activins and follistatin in reproduction
de Kretser, D. M. (2002) · Human Reproduction Update · doi:10.1093/humupd/8.6.529 · Cited by 211
“By crossing these mice with a-subunit deletions with mice having a targeted disruption of the activin Type IIA receptor, it could be demonstrated that in the absence of activin signalling through this receptor, gonadal tumours still occurred but the cachexia was absent (Coerver et al., 1996).”
Kumar, T. R., Palapattu, G. S., Wang, P., Woodruff, T. K., Boime, I., Byrne, M. C., & Matzuk, M. M. (1999) · Molecular Endocrinology · doi:10.1210/me.13.6.851 · Cited by 194
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
“In fact, activin receptors are expressed in a wide variety of tissues including the liver and pituitary, whereas myostatin, activin, and GDF11 have all been demonstrated to influence the physiology of 1 or both of these tissues (62, 81-87).”
BackgroundSmad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Winbanks, C. E., Murphy, K. T., Bernardo, B. C., Qian, H., Liu, Y., Sepulveda, P. V., Beyer, C., Hagg, A., Thomson, R. E., Chen, J. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4976 · Cited by 95
“Smad7 delivery prevents muscle wasting associated with cancer cachexia Because ActRIIB signaling is hypothesized to contribute to the development and progression of cancer cachexia (6, 21, 22), we examined whether rAAV6:Smad7 could prevent muscle wasting in mice bearing cachexia-inducing Colon-26 (C-26) carcinomas.”
BackgroundKim, S. K., Barron, L., Hinck, C. S., Petrunak, E. M., Cano, K. E., Thangirala, A., Iskra, B., Brothers, M., Vonberg, M., Leal, B., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768754 · Cited by 43
Metadata
- Authors
- Coerver, K. A.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1996-05-01
- Volume
- 10
- Issue
- 5
- Pages
- 534-543
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W2009823022
- Cited by
- 149
- References
- 1
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.